Dr Vikas Warikoo, Dr Nikhil Garg


Hepatoblastoma (HBL) is the most common primary liver tumor in
children and accounts for 1% of all pediatric cancers(1). Preterm is a risk
factor although most cases are sporadic, but some are associated with
constitutional genetic abnormalities and malformations, such as the
Beckwith-Wiedemann syndrome and familial adenomatous polyposis
( 2 , 3 ) . Over the last three decades, the annual incidence of
Hepatoblastoma in children has gradually increased(4). Extremely
premature babies with a low birth weight have been reported to have a
greatly increased risk of developing Hepatoblastoma. The increased
survival rates of these premature babies might account for the
increased annual incidence of Hepatoblastomas. Upto 60% of
hepatoblastoma are unresectable on presentation( 5 ) .Due to
chemoresponsiveness of hepatoblastoma neoadjuvant chemotherapy
is used to downsize the tumor for surgical resection. This retrospective
study reviews our experience with multimodality treatment in
management of hepatoblastoma.

Full Text:



D.C. Aronson, P. Czauderna, R. Maibach, G. Perilongo, B. Morland The treatment of hepatoblastoma: its evolution and the current status as per the SIOPEL trials J Indian Assoc Pediatr Surg, 19 (4) (2014), pp. 201-207

Cohen MM Jr. Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. Pediatr Dev Pathol 2005;8:287-304. [PubMed]

Garber JE, Li FP, Kingston JE, et al. Hepatoblastoma and familial adenomatous polyposis. J Natl Cancer Inst 1988;80:1626-8. [PubMed]

Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer 2008;112:416-32. [PubMed]

Mueller Bu, Terrada DL, Finegold MJ. Principles and practice of pediatric oncology. In: Pizzo PA, Poplack DG, editors. Hepatoblastoma. 5th ed. Houston: Lippincott-Williams Wilkins Publishers; 2006. p. 887.

J. Zsíros, R. Maibach, E. Shafford, L. Brugieres, P. Brock, P. Czauderna, et al.Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study

M. Bajpai, K. Pal, S. Agarwala, T. Seth, A.K. GuptaMidterm results with hepatectomy after preoperative chemotherapy in hepatoblastoma

Pediatr Surg Int, 21 (5) (2005 May 1), pp. 364-368

N. Shanmugam, J.X. Scott, V. Kumar, M. Vij, P. Ramachandran, G.Narasimhan, et al.Multidisciplinary management of hepatoblastoma in children: experience from a developing country Pediatr Blood Canc, 64 (3) (2017 Mar e26249 – n/a

Manuprasad, A., Radhakrishnan, V., J, S., Ramakrishnan, A., Ganesan, T., Ganesan, P., Ramamurthy, J., Dhanushkodi, M. and Sagar, T. (2018). Hepatoblastoma: 16-years’ experience from a tertiary cancer centre in India. Pediatric Hematology Oncology Journal, 3(1), pp.13-16.


  • There are currently no refbacks.